Eloxx Pharmaceuticals (ELOX) Reports Q2 Loss of $0.42/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Eloxx Pharmaceuticals Reports Second Quarter 2018 Financial and Operating Results and Provides Business Update
August 7, 2018 4:01 PM EDTCTA approved in Belgium and IND open in the U.S. for investigational drug candidate, ELX-02
On track to initiate Phase 2 clinical trials in cystic fibrosis and cystinosis in 2018
Expanded Leadership Team with Global Pharmaceutical Executives to Accelerate Growth
Company to host webcast and conference call on Tuesday, August 7, 2018 at 4:30 pm ET
WALTHAM, Mass., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel... More
